News

BioAegis Therapeutics, Inc. will present at the Cavendish Global Health Impact Forum in Washington, DC. on May 8, 2017. BioAegis’ technology was chosen as one of the groundbreaking discoveries and innovations at a program billed as “United for Impact: A Multi-sector Collaboration to Transform Health and Lifesciences.” Cavendish brings together participants that “share a passion …

May, 2017: BioAegis Chosen to Present at the Cavendish Washington, DC Health Impact Forum Read More »

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 25, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), presented at the MACRO Trends Conference in Antwerp, Belgium  Presenting for the company was Mr. Steven Cordovano Co-Founder and Vice President of Investor Relations. Read the full press release here: MACROTRENDS Cfx 2017

Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) February 27, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has expanded its clinical advisory board to include John Kellum, MD–noted critical care physician …

February, 2017: BioAegis Therapeutics Announces Addition of Leading Critical Care Nephrologist to its Clinical Advisory Board Read More »

New Patents Issued Across Multiple Geographies in US, Japan and Canada BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2016) BioAegis Therapeutics announces that during 2016 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infectious disease, neurological disease and renal failure. The plasma gelsolin portfolio now includes …

December, 2016: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2016 Read More »

BioAegis Therapeutics announced that it has completed two successful manufacturing runs to produce lyophilized clinical supplies of plasma gelsolin. The drug product in this formulation has already been found to be highly temperature-stable in over two years of stability studies, which are ongoing. The lypophilization of biologics is utilized to eliminate the necessity of cold-chain …

June 20, 2016: Two GMP Drug Product Manufacturing Runs Completed: Lyophilized Clinical Supplies Prepared Read More »

National Institute of Allergy and Infectious Diseases awarded a 3-year $ 2.8 million grant to a partnership between BioAegis and TH Chan Harvard School of Public Health researchers. The grant will advance the study of pGSN replacement as a therapy for antibiotic-resistant pneumonia. The highly competitive R01 grant was responsive to a Request for Applications …

June 9, 2016: BioAegis Therapeutics and TH Chan Harvard School of Public Health Awarded 3-Year $2.8MM NIH Grant to Study Plasma Gelsolin Immunotherapy to Limit Antibiotic-Resistant Pneumonia Read More »

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 22, 2016 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN) won Best Presentation Award at the CM-Equity Conference in Munich, Germany.  Presenting for the company was Mr. Steven Cordovano, Co-Founder and Vice President of Investor Relations. CM-Equity is a diversified financial services firm …

April, 2016: BioAegis Therapeutics Wins Best Presentation Award at the CM-Equity Conference Read More »

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has sold a combination of net operating losses and R&D Credits totaling $544,000. The company’s application to this State of New Jersey’s Technology Business Tax Credit Transfer Program was previously accepted in June.

Company Develops Temperature-Stable Lyophilized Protein BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has successfully completed development of a lyophilized form of plasma gelsolin. Lyophilization is the process of converting the bulk drug substance into a freeze-dried form that can be stored in vials at room temperature. …

November 30, 2015: BioAegis Therapeutics Completes Development of Lyophilized Form of Plasma Gelsolin Read More »

Patents Granted for Renal Failure in Japan and Inflammation in Korea BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – September, 2015) BioAegis Therapeutics announced today patents were recently granted covering plasma gelsolin uses for renal failure in Japan and inflammation in Korea. Further applications in jurisdictions in Asia are also pending.